Overview

Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with pemetrexed disodium may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of two different schedules of bortezomib when given together with pemetrexed disodium and to see how well they work in treating patients with advanced non-small cell lung cancer or other solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, Davis
Collaborator:
Eli Lilly and Company
Treatments:
Bortezomib
Pemetrexed